Working… Menu

Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol (RADiChol)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00973713
Recruitment Status : Unknown
Verified September 2009 by Austin Health.
Recruitment status was:  Recruiting
First Posted : September 9, 2009
Last Update Posted : September 9, 2009
Information provided by:
Austin Health

Brief Summary:

This is a clinical trial investigating the effectiveness and safety of the study drug RAD001 in patients with advanced (metastatic) cholangiocarcinoma. Palliative chemotherapy provides some benefit to this group of patients. However, chemotherapy treatment only shows low rates of radiological response and short times to tumour progression. Therefore, further treatment options are urgently required.

In laboratory studies, RAD001 has been shown to interrupt the signals that cancer cells use to grow, spread and form new blood vessels (angiogenesis). RAD001 has been approved for the treatment of kidney cancer. It has also been approved for use in Australia for the treatment of patients with kidney and liver transplants, and has been used in thousands of patients worldwide for this indication. Preliminary studies suggest that RAD001 may have activity in a range of other cancers. This study will evaluate the activity of RAD001 in advanced cholangiocarcinoma.

Condition or disease Intervention/treatment Phase
Cholangiocarcinoma Drug: RAD001 Phase 2

Detailed Description:

27 patients from approximately four hospitals in Australia will participate in this trial, with approximately 15 patients being enrolled at Austin Health. All participants will receive the same treatment (RAD001 10mg/d given orally).

After screening for eligibility, participants will receive RAD001 10mg/d until tumour progression.

Participants will undergo regular CT scans (every 6 weeks during treatment) to evaluate the effectiveness of treatment. Providing they are tolerating treatment satisfactorily, they may receive study treatment until progression of disease.

Blood samples will be taken during the screening phase and every 3 weeks during the treatment phase of the trial. Participants will be followed-up every 3 months to find out about survival status, new chemotherapy or biological treatment and the outcome of any ongoing adverse events.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 27 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of RAD001 in Advanced Cholangiocarcinoma
Study Start Date : September 2009
Estimated Primary Completion Date : September 2011
Estimated Study Completion Date : March 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Everolimus

Arm Intervention/treatment
Experimental: RAD001 10mg/d Drug: RAD001
Other Name: Everolimus

Primary Outcome Measures :
  1. Tumour control [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 2 years ]
  2. Toxicity [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically/cytologically confirmed adenocarcinoma of gall bladder, intra or extra-hepatic biliary tract
  2. Metastatic or locally advanced (unresectable) disease
  3. Adequate organ function; creatinine<1.5xULN, BR<1.5xULN Neut>1.5, Pts>100
  4. WHO Performance status 0-2
  5. No prior chemotherapy for advanced Cholangiocarcinoma (Prior adjuvant chemotherapy is accepted)
  6. Measurable or non-measurable disease
  7. Informed consent for study participation and donation of tumour tissue for evaluation of relevant translational endpoints

Exclusion Criteria:

  1. Cytotoxic chemotherapy or immunotherapy within 4 weeks prior to enrolment
  2. Prior therapy with mTOR inhibitors (sirolimus, temsirolimus, everolimus)
  3. Known intolerance or hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus)
  4. Uncontrolled diabetes mellitus or hyperlipidaemia
  5. Patients who have any severe and/or uncontrolled medical conditions
  6. Active or uncontrolled severe infection
  7. Cirrhosis, chronic active hepatitis or chronic persistent hepatitis
  8. Severely impaired lung function
  9. Patients with a known history of HIV seropositivity
  10. Patients who have a history of another primary malignancy (Exceptions include non-melanoma skin cancer, carcinoma in situ of uterine cervix, or any other cancer treated with curative intent without evidence of relapse for more than 2 years)
  11. Female patients who are pregnant or nursing (lactating), or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00973713

Layout table for location contacts
Contact: Niall Tebbutt, FRACP +61394965763
Contact: Effie Roiniotis, RN +61394963576

Layout table for location information
Australia, Victoria
Austin Health Recruiting
Melbourne, Victoria, Australia, 3084
Contact: Effie Roiniotis, RN    +61394963576   
Principal Investigator: Niall Tebbutt, FRACP         
Sponsors and Collaborators
Austin Health
Layout table for additonal information
Responsible Party: Niall Tebbutt, Austin Health Identifier: NCT00973713    
Other Study ID Numbers: H2009/3522
First Posted: September 9, 2009    Key Record Dates
Last Update Posted: September 9, 2009
Last Verified: September 2009
Keywords provided by Austin Health:
Advanced cholangiocarcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs